| Differential pricing for pharmaceuticals: reconciling access, R&D and patents PM Danzon, A Towse International journal of health care finance and economics 3, 183-205, 2003 | 435 | 2003 |
| Performance-based risk-sharing arrangements—good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing … LP Garrison Jr, A Towse, A Briggs, G de Pouvourville, J Grueger, PE Mohr, ... Value in health 16 (5), 703-719, 2013 | 335 | 2013 |
| The R&D cost of a new medicine J Mestre-Ferrandiz, J Sussex, A Towse Monograph, 2012 | 236 | 2012 |
| Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report ML Berger, N Dreyer, F Anderson, A Towse, A Sedrakyan, SL Normand Value in Health 15 (2), 217-230, 2012 | 236 | 2012 |
| Learning from Thailand's health reforms A Towse, A Mills, V Tangcharoensathien Bmj 328 (7431), 103-105, 2004 | 219 | 2004 |
| Challenges in the development and reimbursement of personalized medicine—payer and manufacturer perspectives and implications for health economics and outcomes research: a … E Faulkner, L Annemans, L Garrison, M Helfand, AP Holtorf, J Hornberger, ... Value in Health 15 (8), 1162-1171, 2012 | 159 | 2012 |
| Variability of cost‐effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability M Barbieri, M Drummond, R Willke, J Chancellor, B Jolain, A Towse Value in health 8 (1), 10-23, 2005 | 156 | 2005 |
| A health economics approach to US value assessment frameworks—summary and recommendations of the ISPOR special task force report [7] LP Garrison Jr, PJ Neumann, RJ Willke, A Basu, PM Danzon, JA Doshi, ... Value in Health 21 (2), 161-165, 2018 | 152 | 2018 |
| Value‐based differential pricing: Efficient prices for drugs in a global context P Danzon, A Towse, J Mestre‐Ferrandiz Health economics 24 (3), 294-301, 2015 | 149 | 2015 |
| Pharmaceutical pricing in emerging markets: effects of income, competition, and procurement PM Danzon, AW Mulcahy, AK Towse Health economics 24 (2), 238-252, 2015 | 138 | 2015 |
| Can’t get no satisfaction? Will pay for performance help? Toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products A Towse, LP Garrison Pharmacoeconomics 28, 93-102, 2010 | 133 | 2010 |
| Operationalizing value-based pricing of medicines: a taxonomy of approaches J Sussex, A Towse, N Devlin Pharmacoeconomics 31 (1), 1-10, 2013 | 131 | 2013 |
| Should NICE’s threshold range for cost per QALY be raised? Yes A Towse Bmj 338, 2009 | 126* | 2009 |
| Gene therapy: evidence, value and affordability in the US health care system G Hampson, A Towse, SD Pearson, WB Dreitlein, C Henshall Journal of comparative effectiveness research 7 (1), 15-28, 2018 | 125 | 2018 |
| Cost-effectiveness thresholds: economic and ethical issues CP Towse, N Devlin Office of Health Economics, 2002 | 124 | 2002 |
| Using QALYs in cancer: a review of the methodological limitations M Garau, KK Shah, AR Mason, Q Wang, A Towse, MF Drummond Pharmacoeconomics 29, 673-685, 2011 | 120 | 2011 |
| Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare B Jönsson, G Hampson, J Michaels, A Towse, JMG von der Schulenburg, ... The European journal of health economics 20, 427-438, 2019 | 117 | 2019 |
| Toward a broader concept of value: identifying and defining elements for an expanded cost-effectiveness analysis LP Garrison Jr, S Kamal-Bahl, A Towse Value in Health 20 (2), 213-216, 2017 | 117 | 2017 |
| Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation A Towse, CK Hoyle, J Goodall, M Hirsch, J Mestre-Ferrandiz, JH Rex Health Policy 121 (10), 1025-1030, 2017 | 107 | 2017 |
| The economics of gene therapy and of pharmacogenetics P Danzon, A Towse Value in Health 5 (1), 5-13, 2002 | 107 | 2002 |
